In 2006, we saw a 60 year male with stage IV pancreatic cancer. He underwent extensive abdominal surgery to take out a cancer of the pancreas, but the cancer recurred 12 months after surgery. The patient was treated with the standard of care anticancer drug Gemcitabine for four months until the cancer began to grow, despite treatment.
We tested the anticancer drug Mitomycin C — which is rarely used to treat pancreatic cancer – on his tumorgraft. This treatment showed a significant response in the tumorgraft.
The patient received three cycles of Mitomycin C. His blood tumor marker (used to measure the tumor in the blood) was previously 98,000 and based on TumorGraft directed treatments was reduced to under 100. After 22 months he was treated with two additional cycles of Mitomycin C and three cycles of Cisplatin. His cancer remained in remission for five years. The average survival of patients with metastatic pancreatic cancer is approximately six to eight months.
Not every patient will see similar results. This patient was fortunate in that (a) there were drugs available to combat his disease and (b) these drugs were identified as impactful by his tumorgraft.
Question by: DavidSidranskyMD
(Physician - Oncology - Hematology/Oncology (Verified)